A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands

Condition:   Advanced Solid Tumors With Overexpression of Epidermal Growth Factor Receptor (EGFR) or EGFR Ligands
Intervention:   Drug: ABBV-321
Sponsor:   AbbVie
Not yet recruiting - verified July 2017

http://ift.tt/2vlzKbo

Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer

Condition:   Esophageal Cancer
Interventions:   Radiation: Proton Beam Therapy;   Radiation: Photon Radiation Therapy;   Drug: Chemotherapy
Sponsor:   University of Florida
Not yet recruiting - verified July 2017

http://ift.tt/2wdKhSx

Determination of Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

Condition:   Oral Mucositis
Interventions:   Biological: AG013;   Other: Placebo
Sponsor:   Oragenics, Inc.
Recruiting - verified July 2017

http://ift.tt/2vlIP41

Büschelartige Hämangiome („tufted angiomas“) im Kopf-Hals-Bereich

Zusammenfassung

Hintergrund

„Tufted angiomas" (TA, büschelartige Hämangiome) sind seltene, gutartige, vaskuläre Tumoren, die meist in der Kutis und Subkutis lokalisiert sind, während der Kindheit auftreten und langsam größenprogredient sind. TA stellen eine Unterform des lobulären, kapillären Hämangioms dar. Dies ist die erste Studie, die einen Überblick über aktuelle Literatur und einen klinischen Erfahrungsbericht zu dieser seltenen Entität im Kopf-Hals-Bereich mit nichtdermatologischer Manifestation darbietet.

Methodik

Es erfolgte eine selektive Literaturrecherche über MEDLINE und Google Scholar. Zusätzlich führten die Autoren eine ICD-10-basierte Datenbankrecherche (SAP) zu Hämangiomen (D18.0) an einer der größten Universitätskliniken Europas durch.

Ergebnisse

Es wurden 13 Publikationen mit 16 Fällen eines TA im Kopf-Hals-Bereich identifiziert. Männer waren mit 70,6 % am häufigsten von TA betroffen. Das mittlere Patientenalter zum Zeitpunkt der operativen Entfernung des Tumors lag bei 31,5 Jahren; die mittlere Größe der Raumforderungen lag bei 16,3 mm. Die Autoren berichten zusätzlich über ein intraorbitales TA eines männlichen Patienten, der sich mit Schwellung und Rötung des linken Oberlids vorstellte. Die Computertomographie zeigte einen linksseitigen suprabulbären Tumor mit einem Durchmesser von 13 mm. Der Tumor wurde in Vollnarkose via Blepharoplastik-Zugang transkutan exzidiert. Die Heilung verlief ohne Komplikationen.

Diskussion

Bisher wurde lediglich ein Fallbericht über die operative Entfernung eines intraorbitalen TA publiziert. Die vorliegende Arbeit gibt einen Überblick über Epidemiologie, therapeutische Möglichkeiten und Differenzialdiagnosen.

http://ift.tt/2uQprsQ

A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors

Abstract

Head and neck high grade malignant peripheral nerve sheath tumors (HN-MPNSTs) are rare highly aggressive soft tissue sarcomas that show overlapping morphologic and immunophenotypic features with melanoma and other high grade sarcomas, resulting in diagnostic challenges, particularly in sporadic settings. Recent discoveries have implicated loss of function mutations in the polycomb repressive complex 2 (PRC2) components, including EED or SUZ12 genes, as one of the leading pathogenetic mechanisms in high grade MPNST. MPNSTs with PRC2 loss are associated with complete loss of trimethylation at lysine 27 of histone H3 (H3K27me3), which emerged as a reliable immunohistochemical marker in the diagnosis of sporadic and radiation induced MPNST. As the diagnosis of MPNST in the HN is particularly challenging to distinguish from melanoma and other sarcoma types, we carried out a clinicopathologic analysis on HN-MPNST patients managed at our institution over a 20-year period (1997–2016), using the latest diagnostic criteria including H3K27me3 staining and other molecular investigations. The overall survival of HN-MPNST was compared with other HN soft tissue sarcomas. The diagnosis of HN-MPNST was confirmed in 13 patients (seven males and six females), with a mean age of 31 years; with 3 (23%) patients being of pediatric age. The most common site was the neck soft tissue (77%). Two-thirds of patients (n = 9) had stigmata of NF1, three had prior radiotherapy and only one developed a de novo MPNST. All except one tumor (86%) tested showed loss of H3K27me3 expression, including all non-NF1 patients. The 2 and 5-year DSS rates were 50 and 30%. The 2-year DFS rate was 21%. Adverse predictors on DSS included adult age (p = 0.011), prior-history of RT (p = 0.003) and recurrence (p = 0.003). Compared to other molecularly confirmed subsets of HN sarcomas (Ewing and Ewing-like sarcoma, rhabdomyosarcoma and synovial sarcoma), HN-MPNST had the worst overall survival (p < 0.0001). We conclude that HN-MPNSTs are highly aggressive sarcomas associated with an unfavorable outcome and the utility of H3K27me3 IHC stains in the evaluation of MPNST is a reliable ancillary diagnostic adjunct.

http://ift.tt/2tQFJAN

A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors

Abstract

Head and neck high grade malignant peripheral nerve sheath tumors (HN-MPNSTs) are rare highly aggressive soft tissue sarcomas that show overlapping morphologic and immunophenotypic features with melanoma and other high grade sarcomas, resulting in diagnostic challenges, particularly in sporadic settings. Recent discoveries have implicated loss of function mutations in the polycomb repressive complex 2 (PRC2) components, including EED or SUZ12 genes, as one of the leading pathogenetic mechanisms in high grade MPNST. MPNSTs with PRC2 loss are associated with complete loss of trimethylation at lysine 27 of histone H3 (H3K27me3), which emerged as a reliable immunohistochemical marker in the diagnosis of sporadic and radiation induced MPNST. As the diagnosis of MPNST in the HN is particularly challenging to distinguish from melanoma and other sarcoma types, we carried out a clinicopathologic analysis on HN-MPNST patients managed at our institution over a 20-year period (1997–2016), using the latest diagnostic criteria including H3K27me3 staining and other molecular investigations. The overall survival of HN-MPNST was compared with other HN soft tissue sarcomas. The diagnosis of HN-MPNST was confirmed in 13 patients (seven males and six females), with a mean age of 31 years; with 3 (23%) patients being of pediatric age. The most common site was the neck soft tissue (77%). Two-thirds of patients (n = 9) had stigmata of NF1, three had prior radiotherapy and only one developed a de novo MPNST. All except one tumor (86%) tested showed loss of H3K27me3 expression, including all non-NF1 patients. The 2 and 5-year DSS rates were 50 and 30%. The 2-year DFS rate was 21%. Adverse predictors on DSS included adult age (p = 0.011), prior-history of RT (p = 0.003) and recurrence (p = 0.003). Compared to other molecularly confirmed subsets of HN sarcomas (Ewing and Ewing-like sarcoma, rhabdomyosarcoma and synovial sarcoma), HN-MPNST had the worst overall survival (p < 0.0001). We conclude that HN-MPNSTs are highly aggressive sarcomas associated with an unfavorable outcome and the utility of H3K27me3 IHC stains in the evaluation of MPNST is a reliable ancillary diagnostic adjunct.

http://ift.tt/2tQFJAN

A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors

Abstract

Head and neck high grade malignant peripheral nerve sheath tumors (HN-MPNSTs) are rare highly aggressive soft tissue sarcomas that show overlapping morphologic and immunophenotypic features with melanoma and other high grade sarcomas, resulting in diagnostic challenges, particularly in sporadic settings. Recent discoveries have implicated loss of function mutations in the polycomb repressive complex 2 (PRC2) components, including EED or SUZ12 genes, as one of the leading pathogenetic mechanisms in high grade MPNST. MPNSTs with PRC2 loss are associated with complete loss of trimethylation at lysine 27 of histone H3 (H3K27me3), which emerged as a reliable immunohistochemical marker in the diagnosis of sporadic and radiation induced MPNST. As the diagnosis of MPNST in the HN is particularly challenging to distinguish from melanoma and other sarcoma types, we carried out a clinicopathologic analysis on HN-MPNST patients managed at our institution over a 20-year period (1997–2016), using the latest diagnostic criteria including H3K27me3 staining and other molecular investigations. The overall survival of HN-MPNST was compared with other HN soft tissue sarcomas. The diagnosis of HN-MPNST was confirmed in 13 patients (seven males and six females), with a mean age of 31 years; with 3 (23%) patients being of pediatric age. The most common site was the neck soft tissue (77%). Two-thirds of patients (n = 9) had stigmata of NF1, three had prior radiotherapy and only one developed a de novo MPNST. All except one tumor (86%) tested showed loss of H3K27me3 expression, including all non-NF1 patients. The 2 and 5-year DSS rates were 50 and 30%. The 2-year DFS rate was 21%. Adverse predictors on DSS included adult age (p = 0.011), prior-history of RT (p = 0.003) and recurrence (p = 0.003). Compared to other molecularly confirmed subsets of HN sarcomas (Ewing and Ewing-like sarcoma, rhabdomyosarcoma and synovial sarcoma), HN-MPNST had the worst overall survival (p < 0.0001). We conclude that HN-MPNSTs are highly aggressive sarcomas associated with an unfavorable outcome and the utility of H3K27me3 IHC stains in the evaluation of MPNST is a reliable ancillary diagnostic adjunct.

http://ift.tt/2tQFJAN